SELANK: The Anti-Anxiety Peptide That Boosts Cognition Without Sedation

How this tuftsin-derived peptide modulates GABA to reduce anxiety while enhancing cognitive function — the nootropic anxiolytic researchers have been looking for.

Source: https://indexalabs.com/blog/selank-anti-anxiety-peptide-cognition-without-sedation Abstract: SELANK is a synthetic peptide derived from the immunopeptide tuftsin, developed alongside SEMAX at the Russian Academy of Sciences. It provides potent anxiolytic (anti-anxiety) effects through GABA modulation without the sedation, dependency, or cognitive impairment associated with benzodiazepines. Uniquely, SELANK also enhances cognitive function — making it the rare compound that reduces anxiety while simultaneously improving mental performance.

What Is SELANK? The Anxiolytic That Enhances Cognition

SELANK is a synthetic heptapeptide derived from tuftsin — a naturally occurring immunostimulatory peptide — with an added Pro-Gly-Pro C-terminal sequence for enzymatic stability (the same stabilisation strategy used in SEMAX).

Development history: Created at the Institute of Molecular Genetics, Russian Academy of Sciences, SELANK was designed to address a fundamental limitation of existing anti-anxiety medications: they all impair cognition. Benzodiazepines cause sedation, memory impairment, and dependency. SSRIs take weeks to work and have their own side effect burden. The researchers sought a compound that could reduce anxiety while preserving — or even enhancing — cognitive function.

Key characteristics:

• Peptide class: Synthetic tuftsin analogue with nootropic-anxiolytic properties
• Core sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Administration: Intranasal (nasal drops or spray)
• Russian trade name: Selank® (0.15% nasal drops)
• Regulatory status: Approved medication in Russia; research compound internationally
• Unique property: Dual anxiolytic + nootropic activity — almost unheard of in pharmacology

Why this matters: In the world of psychopharmacology, reducing anxiety almost always comes at the cost of cognitive function. SELANK breaks this paradigm by working through mechanisms that simultaneously calm and sharpen the mind.

How SELANK Works: GABA, Serotonin & Immune Modulation

SELANK’s anxiolytic and cognitive effects arise from several interconnected mechanisms:

1. GABA System Modulation (Primary anxiolytic mechanism):

• SELANK modulates GABA-A receptor sensitivity, enhancing inhibitory neurotransmission
• Unlike benzodiazepines, which act as direct positive allosteric modulators (flooding the GABA system), SELANK acts as a more subtle modulator
• This “softer” GABA enhancement produces anxiolysis without sedation or cognitive impairment
• No risk of tolerance, dependency, or withdrawal — the pharmacological holy grail for anxiolytics

2. Serotonin System:

• Influences serotonin metabolism and receptor sensitivity
• Stabilises mood without the full serotonergic effects (and side effects) of SSRIs
• Particularly affects 5-HT1A receptors, which are directly implicated in anxiety regulation

3. BDNF and Neurotrophic Effects:

• Like its sister peptide SEMAX, SELANK upregulates brain-derived neurotrophic factor
• This provides the cognitive enhancement component — improved memory, learning, and neuroplasticity
• BDNF elevation also has independent anxiolytic effects, as low BDNF is associated with anxiety and depression

4. Immune Modulation (via tuftsin heritage):

• Tuftsin is naturally involved in immune regulation
• SELANK retains immunomodulatory properties, potentially reducing neuroinflammation
• Neuroinflammation is increasingly recognised as a contributor to anxiety and mood disorders
• This immune-brain axis effect may explain some of SELANK’s therapeutic breadth

5. Enkephalin Metabolism:

• SELANK inhibits the enzymes that break down enkephalins (endogenous opioid peptides)
• This results in a mild, natural mood-elevating effect without the risks of opioid receptor agonism
• Contributes to the general sense of well-being users report

Anti-Anxiety Benefits: How SELANK Compares to Benzos

SELANK’s anxiolytic profile is remarkable precisely because of what it doesn’t do:

What SELANK provides:

• Significant reduction in generalised anxiety
• Reduced worry, rumination, and anticipatory anxiety
• Calmer stress response — ability to stay composed under pressure
• Social anxiety reduction without the numbing effect of benzodiazepines
• Improved emotional regulation and resilience

What SELANK does NOT cause (unlike benzodiazepines):

• ❌ No sedation or drowsiness
• ❌ No cognitive impairment or “brain fog”
• ❌ No memory problems (actually improves memory)
• ❌ No physical dependency
• ❌ No withdrawal syndrome
• ❌ No tolerance development (maintaining effectiveness over time)
• ❌ No psychomotor impairment
• ❌ No respiratory depression risk

The comparison table:

Factor	SELANK	Benzodiazepines
Anxiolytic effect	Moderate-strong	Strong
Onset	15–30 minutes	15–45 minutes
Sedation	None	Significant
Cognitive effect	Enhancement	Impairment
Memory	Improved	Impaired
Dependency risk	None	High
Withdrawal	None	Severe (potentially dangerous)
Tolerance	Not reported	Develops within weeks
Safe to stop suddenly	Yes	No (must taper)

Clinical implications: SELANK offers a compelling option for individuals who need anxiety relief but cannot afford cognitive impairment — students, professionals, creatives, and anyone who needs to stay sharp while managing anxiety.

The Cognitive Enhancement Side: Focus Meets Calm

SELANK’s cognitive benefits make it unique among anxiolytics:

Enhanced focus under stress:

• Anxiety is one of the biggest cognitive performance killers — racing thoughts, distractibility, and threat-monitoring all steal cognitive resources
• By reducing anxiety, SELANK frees up cognitive bandwidth for focused work
• But it goes further: BDNF upregulation actively enhances the neural circuits responsible for attention and working memory
• The result is a calm, focused state that researchers describe as “optimal cognitive arousal”

Memory improvement:

• SELANK enhances both short-term working memory and long-term memory consolidation
• Particularly effective for learning under stress — exam preparation, high-pressure projects, etc.
• The combination of reduced anxiety + enhanced BDNF creates ideal conditions for memory formation

Creative and verbal fluency:

• Anxiety restricts creative thinking by activating threat-focused, narrow attention
• SELANK’s anxiolytic effect opens up broader associative thinking
• Users report improved verbal fluency, creative problem-solving, and “mental flexibility”

Comparison with SEMAX (its sister peptide):

• SEMAX: Primarily cognitive enhancement with mild anxiolytic effects
• SELANK: Primarily anxiolytic with significant cognitive enhancement
• Combined protocol: Many researchers use SEMAX in the morning for cognitive demands and SELANK in the afternoon for stress management
• Both share intranasal delivery, similar safety profiles, and can be used in the same cycle

SELANK Dosing Protocol and Administration

Intranasal administration protocol:

Standard dosing:

• Concentration: 0.15% solution (1.5 mg/mL) — the standard Russian pharmaceutical formulation
• Dose: 250–500 mcg per administration
• Frequency: 2–3 times daily
• Timing: Can be taken throughout the day; unlike SEMAX, SELANK does not interfere with sleep (may actually improve it)
• Cycle: 14–21 days on, followed by a 7–14 day break

Beginner protocol:

• Start with 250 mcg (approximately 2–3 drops of 0.15% solution) once daily
• Assess response over 3–5 days — many users notice effects within the first few days
• Increase to 250 mcg twice daily (morning and afternoon)
• After one week, evaluate and adjust up to 500 mcg per dose if needed

For acute anxiety situations:

• A single dose of 500 mcg can be taken 15–30 minutes before an anxiety-provoking situation
• Presentations, social events, difficult conversations, etc.
• This “as-needed” use can supplement a regular cycling protocol

Administration technique:

1. Same nasal delivery method as SEMAX
2. Alternate nostrils for each drop
3. Avoid blowing nose for 10–15 minutes after administration
4. Can be taken with or without food

Stacking with SEMAX:

• Morning: SEMAX 200–400 mcg (cognitive enhancement)
• Afternoon: SELANK 250–500 mcg (anxiety management + sustained cognition)
• This combination covers both the nootropic and anxiolytic spectrum

Storage: Refrigerate reconstituted solution. Stable for approximately 30 days when properly stored.

Safety Profile and the Future of Peptide Anxiolytics

SELANK’s safety profile is exceptional — consistent with over 15 years of clinical use in Russia:

Reported side effects (rare):

• Mild nasal irritation or dryness
• Occasional mild fatigue during the first few days (paradoxical — may reflect the body adjusting to lower anxiety levels)
• Very rarely, mild headache

No serious adverse effects have been reported in the clinical literature. This is particularly notable given the millions of doses administered in Russian clinical practice.

Drug interactions:

• No significant interactions reported with common medications
• May theoretically enhance the sedative effects of benzodiazepines if used concurrently (though this combination is generally unnecessary)
• Safe to use alongside SEMAX, caffeine, and most supplements

The broader significance: SELANK represents a proof of concept that anxiolytic compounds don’t have to impair cognition. This has profound implications for:

• Anxiety treatment: Millions of people avoid treating their anxiety because they can’t afford the cognitive cost of current medications
• Performance optimisation: SELANK allows anxiety management without sacrificing mental sharpness
• Neuroscience: The tuftsin-derived mechanism opens new research avenues into immune-brain interactions and peptide-based mental health treatments

SELANK and the future of peptide psychiatry: As Western neuroscience increasingly recognises the role of neuroinflammation, neurotrophic factors, and peptide signalling in mental health, compounds like SELANK may move from the fringes of nootropic culture to mainstream psychiatric research. Its safety profile, dual mechanism, and decades of clinical data make it one of the most compelling candidates for this transition.